File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Conjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses in vitro
  • Basic View
  • Metadata View
  • XML View
TitleConjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses in vitro
 
AuthorsCheung, WH2 4
Chan, VSF2 1
Pang, HW4
Wong, MK4
Guo, ZH3
Tam, PKH2
Che, CM4
Lin, CL2 1
Yu, WY5 4
 
Issue Date2009
 
PublisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/bc
 
CitationBioconjugate Chemistry, 2009, v. 20 n. 1, p. 24-31 [How to Cite?]
DOI: http://dx.doi.org/10.1021/bc800167q
 
AbstractNasopharyngeal carcinoma is a neoplasm with a high incidence in Southeast Asia, and it is strongly associated with Epstein-Barr virus (EBV) activation involving the expression of a weakly immunogenic protein, namely, latent membrane protein (LMP)-2. Previous immunological studies already identified the human leukocyte antigen (HLA)-All restricted peptide epitope (SSCSSCPLSK) in the LMP-2 antigen. In this work, we prepared gold nanoparticle (AuNP)-peptide conjugate 1 by treating the nanoparticles with the Af-cysteinated LMP-2 epitope. The AuNP-peptide conjugates have been characterized by TEM (15-24 nm in diameter) and UV-vis spectroscopy (surface plasmon resonance absorption band at λmax = 520 nm). In the presence of a CALNN capping peptide, the AuNP-peptide conjugates are stable in solution without aggregation at room temperature for at least 48 h. By ELIspot studies, AuNP-peptide conjugate 1 was found to elicit a significantly stronger INF-γ response [number of spot forming cells (SPC) = 727 ± 198] from peripheral blood mononuclear cells of healthy HLA-A11 donors when compared to that induced by the unconjugated LMP-2 peptides (SFC = 73 ± 28). Further studies showed that dendritic cells treated with conjugate 1 can effect CD8+ T-cell activation leading to epitope-specific cytotoxic T lymphocyte killing responses in vitro. © 2009 American Chemical Society.
 
ISSN1043-1802
2012 Impact Factor: 4.58
2012 SCImago Journal Rankings: 1.814
 
DOIhttp://dx.doi.org/10.1021/bc800167q
 
ISI Accession Number IDWOS:000262659700005
Funding AgencyGrant Number
Innovation and Technology Commission (HKSAR)ITS/211/01
University of Hong Kong
UGC20600433
NSFC/RGCN_HKU 721/04
RGCCERGHKU 7444/03M
Areas of Excellence SchemeAoE/P-10/01
Funding Information:

We acknowledge the financial support of the Innovation and Technology Fund (ITS/211/01) administered by the Innovation and Technology Commission (HKSAR), The University of Hong Kong (University Development Fund and UGC matching grant No. 20600433), NSFC/RGC (N_HKU 721/04), RGCCERG (HKU 7444/03M), and the Areas of Excellence Scheme (AoE/P-10/01) established under the University Grants Council, HKSAR.

 
ReferencesReferences in Scopus
 
GrantsDevelopment and clinical evaluation of peptide vaccines for immunotherapy of Epstein-Barr virus-positive nasopharyngeal carcinoma
Institute of molecular technology for drug discovery and synthesis
 
DC FieldValue
dc.contributor.authorCheung, WH
 
dc.contributor.authorChan, VSF
 
dc.contributor.authorPang, HW
 
dc.contributor.authorWong, MK
 
dc.contributor.authorGuo, ZH
 
dc.contributor.authorTam, PKH
 
dc.contributor.authorChe, CM
 
dc.contributor.authorLin, CL
 
dc.contributor.authorYu, WY
 
dc.date.accessioned2011-03-28T09:25:21Z
 
dc.date.available2011-03-28T09:25:21Z
 
dc.date.issued2009
 
dc.description.abstractNasopharyngeal carcinoma is a neoplasm with a high incidence in Southeast Asia, and it is strongly associated with Epstein-Barr virus (EBV) activation involving the expression of a weakly immunogenic protein, namely, latent membrane protein (LMP)-2. Previous immunological studies already identified the human leukocyte antigen (HLA)-All restricted peptide epitope (SSCSSCPLSK) in the LMP-2 antigen. In this work, we prepared gold nanoparticle (AuNP)-peptide conjugate 1 by treating the nanoparticles with the Af-cysteinated LMP-2 epitope. The AuNP-peptide conjugates have been characterized by TEM (15-24 nm in diameter) and UV-vis spectroscopy (surface plasmon resonance absorption band at λmax = 520 nm). In the presence of a CALNN capping peptide, the AuNP-peptide conjugates are stable in solution without aggregation at room temperature for at least 48 h. By ELIspot studies, AuNP-peptide conjugate 1 was found to elicit a significantly stronger INF-γ response [number of spot forming cells (SPC) = 727 ± 198] from peripheral blood mononuclear cells of healthy HLA-A11 donors when compared to that induced by the unconjugated LMP-2 peptides (SFC = 73 ± 28). Further studies showed that dendritic cells treated with conjugate 1 can effect CD8+ T-cell activation leading to epitope-specific cytotoxic T lymphocyte killing responses in vitro. © 2009 American Chemical Society.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationBioconjugate Chemistry, 2009, v. 20 n. 1, p. 24-31 [How to Cite?]
DOI: http://dx.doi.org/10.1021/bc800167q
 
dc.identifier.doihttp://dx.doi.org/10.1021/bc800167q
 
dc.identifier.epage31
 
dc.identifier.hkuros155039
 
dc.identifier.isiWOS:000262659700005
Funding AgencyGrant Number
Innovation and Technology Commission (HKSAR)ITS/211/01
University of Hong Kong
UGC20600433
NSFC/RGCN_HKU 721/04
RGCCERGHKU 7444/03M
Areas of Excellence SchemeAoE/P-10/01
Funding Information:

We acknowledge the financial support of the Innovation and Technology Fund (ITS/211/01) administered by the Innovation and Technology Commission (HKSAR), The University of Hong Kong (University Development Fund and UGC matching grant No. 20600433), NSFC/RGC (N_HKU 721/04), RGCCERG (HKU 7444/03M), and the Areas of Excellence Scheme (AoE/P-10/01) established under the University Grants Council, HKSAR.

 
dc.identifier.issn1043-1802
2012 Impact Factor: 4.58
2012 SCImago Journal Rankings: 1.814
 
dc.identifier.issue1
 
dc.identifier.pmid19102689
 
dc.identifier.scopuseid_2-s2.0-61849144830
 
dc.identifier.spage24
 
dc.identifier.urihttp://hdl.handle.net/10722/132491
 
dc.identifier.volume20
 
dc.languageeng
 
dc.publisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/bc
 
dc.publisher.placeUnited States
 
dc.relation.ispartofBioconjugate Chemistry
 
dc.relation.projectDevelopment and clinical evaluation of peptide vaccines for immunotherapy of Epstein-Barr virus-positive nasopharyngeal carcinoma
 
dc.relation.projectInstitute of molecular technology for drug discovery and synthesis
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAntigens, Viral - immunology
 
dc.subject.meshCD8-Positive T-Lymphocytes - immunology
 
dc.subject.meshCytotoxicity, Immunologic
 
dc.subject.meshGold
 
dc.subject.meshHerpesvirus 4, Human - immunology
 
dc.subject.meshHumans
 
dc.subject.meshLymphocyte Activation - immunology
 
dc.subject.meshMetal Nanoparticles - chemistry
 
dc.subject.meshT-Lymphocytes, Cytotoxic - immunology
 
dc.subject.meshViral Matrix Proteins - chemistry - immunology
 
dc.titleConjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses in vitro
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Cheung, WH</contributor.author>
<contributor.author>Chan, VSF</contributor.author>
<contributor.author>Pang, HW</contributor.author>
<contributor.author>Wong, MK</contributor.author>
<contributor.author>Guo, ZH</contributor.author>
<contributor.author>Tam, PKH</contributor.author>
<contributor.author>Che, CM</contributor.author>
<contributor.author>Lin, CL</contributor.author>
<contributor.author>Yu, WY</contributor.author>
<date.accessioned>2011-03-28T09:25:21Z</date.accessioned>
<date.available>2011-03-28T09:25:21Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Bioconjugate Chemistry, 2009, v. 20 n. 1, p. 24-31</identifier.citation>
<identifier.issn>1043-1802</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/132491</identifier.uri>
<description.abstract>Nasopharyngeal carcinoma is a neoplasm with a high incidence in Southeast Asia, and it is strongly associated with Epstein-Barr virus (EBV) activation involving the expression of a weakly immunogenic protein, namely, latent membrane protein (LMP)-2. Previous immunological studies already identified the human leukocyte antigen (HLA)-All restricted peptide epitope (SSCSSCPLSK) in the LMP-2 antigen. In this work, we prepared gold nanoparticle (AuNP)-peptide conjugate 1 by treating the nanoparticles with the Af-cysteinated LMP-2 epitope. The AuNP-peptide conjugates have been characterized by TEM (15-24 nm in diameter) and UV-vis spectroscopy (surface plasmon resonance absorption band at &#955;max = 520 nm). In the presence of a CALNN capping peptide, the AuNP-peptide conjugates are stable in solution without aggregation at room temperature for at least 48 h. By ELIspot studies, AuNP-peptide conjugate 1 was found to elicit a significantly stronger INF-&#947; response [number of spot forming cells (SPC) = 727 &#177; 198] from peripheral blood mononuclear cells of healthy HLA-A11 donors when compared to that induced by the unconjugated LMP-2 peptides (SFC = 73 &#177; 28). Further studies showed that dendritic cells treated with conjugate 1 can effect CD8+ T-cell activation leading to epitope-specific cytotoxic T lymphocyte killing responses in vitro. &#169; 2009 American Chemical Society.</description.abstract>
<language>eng</language>
<publisher>American Chemical Society. The Journal&apos;s web site is located at http://pubs.acs.org/bc</publisher>
<relation.ispartof>Bioconjugate Chemistry</relation.ispartof>
<subject.mesh>Antigens, Viral - immunology</subject.mesh>
<subject.mesh>CD8-Positive T-Lymphocytes - immunology</subject.mesh>
<subject.mesh>Cytotoxicity, Immunologic</subject.mesh>
<subject.mesh>Gold</subject.mesh>
<subject.mesh>Herpesvirus 4, Human - immunology</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Lymphocyte Activation - immunology</subject.mesh>
<subject.mesh>Metal Nanoparticles - chemistry</subject.mesh>
<subject.mesh>T-Lymphocytes, Cytotoxic - immunology</subject.mesh>
<subject.mesh>Viral Matrix Proteins - chemistry - immunology</subject.mesh>
<title>Conjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses in vitro</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1021/bc800167q</identifier.doi>
<identifier.pmid>19102689</identifier.pmid>
<identifier.scopus>eid_2-s2.0-61849144830</identifier.scopus>
<identifier.hkuros>155039</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-61849144830&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>20</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>24</identifier.spage>
<identifier.epage>31</identifier.epage>
<identifier.isi>WOS:000262659700005</identifier.isi>
<publisher.place>United States</publisher.place>
<relation.project>Development and clinical evaluation of peptide vaccines for immunotherapy of Epstein-Barr virus-positive nasopharyngeal carcinoma</relation.project>
<relation.project>Institute of molecular technology for drug discovery and synthesis</relation.project>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Institute of Molecular Technology for Drug Discovery and Synthesis, Hong Kong
  3. Imperial College London
  4. Hong Kong Polytechnic University
  5. Hong Kong University of Science and Technology